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Figure 3. Ptyerygium inversum unguis in 4 participants with severe cGVHD characterized by sclerotic involvement and lung disease. Clockwise from left upper:
Patient 7, 3, 4, 12.
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with myofascial sclerotic cGVHD were signiﬁcantly more
likely than those with other types of skin cGVHD to have
preceding peripheral edema (6/6 vs. 0/4, p¼0.005). In addi-
tion, patients with severe cGVHD were signiﬁcantly more
likely than those with mild or moderate cGVHD to have
preceding peripheral edema (5/5 vs. 1/5, p¼0.05). Nail dys-
trophy was present in 7/12 (58%) patients in our cohort, and
was signiﬁcantly more likely to occur in patients with myo-
fascial sclerotic cGVHD than those with other forms of skin
cGVHD (7/7 vs. 1/5, p¼0.01). Pterygium inversum inguis, a
speciﬁc form of nail dystrophy, was present in 4 of 12 pa-
tients, and was signiﬁcantly more likely to occur in patients
awaiting lung transplantation (3/4 vs. 0/8, p¼0.02). This
study represents the largest cohort of pediatric patients with
skin cGVHD reported in the literature and suggests that pe-
ripheral eosinophilia, edema, and nail dystrophy are har-
bingers of severe cGVHD of the skin in children.251
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Background: While it has been noted clinically that the
mean corpuscular volume (MCV) for HSCT recipients may
tend to increase over time, literature describing changes to
mean corpuscular volume (MCV) following pediatric HSCT is
very limited. Macrocytosis is of clinical interest because it
may signal underlying bone marrow dysfunction. Conse-
quently, understanding the natural course of changes in the
MCV over time is important.Methods: We conducted a retrospective chart review of all
pediatric patients undergoing allogeneic (allo) or autologous
(auto) HSCT at the Medical University of South Carolina
during July 1, 2007-June 30, 2012 who have survived for >1
year after transplant without relapse. The sample included
16 auto-HSCT patients (10 patients with incomplete data)
and 32 allo-HSCT patients. Baseline MCV values were
recorded both at baseline (PBSC collection date for auto pa-
tients, HSCT admission date for allo patients) and at speciﬁc
intervals post-HSCT. Data was analyzed to identify the
presence of macrocytosis based on age-speciﬁc normal
values, the trend of MCV changes with time, and the time of
maximum change in MCV. Linear regression was used to
evaluate associations between factors and MCV changes.
Statistical signiﬁcance was accepted at P<0.05.
Results: Macrocytosis was present at baseline in 19% of the
allo patients and 0% of the auto patients. Maximum mean
MCV change for allo and auto patients was at 90 days post-
HSCT. At day 90, allo patients had a mean increase in MCV of
5.77 ﬂ (95% CI 2.77- 8.77), and auto patients had a mean
increase in MCV of 8.33 ﬂ (95% CI 2.80-13.87). For allo pa-
tients, 56%, 32%, and 40% were macrocytic at days 90, 365,
and 730 post-HSCT. For auto patients, 67%, 40%, and 40%
were macrocytic at days 90, 365, and 730 post-HSCT. For allo
patients, MCV changes were associated with ABO in-
compatibility (p¼0.043) but not with age, sex, diagnosis,
disease status at HSCT, prep regimen, graft source, cell dose,
GVHD, neutrophil engraftment, or platelet engraftment.
Compared to patients with no ABO incompatibility, the mean
change in MCV at day 90 was 14.38 ﬂ less for patients with
minor ABO incompatibility but was not signiﬁcantly different
for patients with major ABO incompatibility. For auto pa-
tients, MCV changes had a positive association with
neutrophil engraftment (p¼0.049) with a trend towards an
association with cell dose (p¼0.071) but not with age, sex,
diagnosis, initial chemotherapy, disease status at HSCT, prep
regimen, or platelet engraftment. For each additional day
increase in neutrophil engraftment, themean change inMCV
at day 90 is expected to increase by 1.91 ﬂ.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S165eS183 S173Conclusion: Macrocytosis develops and persists up to two
years post-HSCT in a substantial proportion of allo and auto
HSCT patients. Macrocytosis may be related to bone marrow
microenvironment injury from prep regimens.252
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This retrospective study compared the outcome following
three different conditioning regimens used for allogeneic
haematopoietic stem cell transplantation (SCT) of 445 Nordic
children with acute lymphoblastic leukemia (ALL). The chil-
dren received myeloablative conditioning with cyclophos-
phamide (n¼325), Cytarabine (Ara-C) (n¼68), Etoposide
(n¼47) or other (n¼8) in combination with total body irra-
diation (85%). The mean age at SCT was 9.0 years (0.58-
17.42), the median follow up 9.25 years (1.89-20.3). Grafts
were from sibling donors (n¼150), unrelated donors (n¼274)
or other related (n¼24). Disease status at SCT was CR1
(n¼176), CR2 (n¼204), CR3 (n¼51) or in relapse (n¼14).
Children conditioned with Etoposide and Ara-C had signiﬁ-
cantly better overall survival compared with those who
received Cyclophosphamide (pOS 0.74, 0.65 and 0.44
respectively, p<0.0001). The cumulative incidence of relapse
was 0.4 (0.35-0.46) for the Cyclophosphamide group vs 0.23
and 0.19 (p¼0.008) for the Etoposide and Ara-C group. The
cumulative incidence for non leukemia mortality was 0.17 vs
0.07 and 0.16 (p¼0.19) respectively. In a multivariate analysis
conditioning regimen was an independent prognostic factor
with the hazard ratio of 0.44 (Etoposide) and 0.56 (Ara-C),
overall p¼0.002. In conclusion we suggest that high dose
Etoposide is superior to high dose Cyclophosphamide in
conditioning for childhood ALL.253
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Background: While studies have suggested efﬁcacy of
extracorporeal photopheresis (ECP) in children with re-
fractory GVHD, few have systematically addressed the
safety proﬁle and efﬁciency of this modality. Two
frequently used instruments are UVAR-XTS and more
recently CELLEX (Therakos). Whereas UVAR-XTS is a
discontinuous ﬂow circuit designed to treat adults,
CELLEX is a near-continuous ﬂow system, decreasing
ﬂuid shifts and hypotension. In our center CELLEX is now
the modality of choice, but some patients had both during
the transition.
Methods: Retrospective chart review of patients who un-
derwent ECP with both UVAR-XTS and CELLEX in-
struments for steroid-refractory acute or chronic GVHD from
9/10-8/13 to compare treatment times, percentages of cells
treated, and complication rates (line occlusions, pre-proce-
dure blood transfusions, and major hemodynamic changes).
Mann-Whitney and Fisher’s Exact Test were used for statis-
tical analyses.
Results: Ten patients met criteria. Median age was 10.3
years (range 7.5-26.9) and weight 31.7 kg (21.8-65). A total
of 381 procedures were analyzed: 225 (59%) with UVAR-
XTS and 156 (41%) with CELLEX. Types of anti-
coagulation used included citrate and heparin. Transfusion
criteria pre-procedure were hematocrit >30% and platelet
count >50,000/ml (for patients on heparin) or > 30,000/
mL (for patients on citrate anticoagulation). Mean treat-
ment times were UVAR-XTS 190 min (65-440) and
CELLEX 117 min (50-270), p<0.0001. Average blood
volume processed with UVAR was 3.5 cycles (3-6) and
CELLEX 1118 mls (206-1626). There were 43 UVAR-XTS
and 92 CELLEX procedures with mononuclear cell (MNC)
processing data available. Mean percentage of MNCs
treated was 27% (8.6-66%) for UVAR-XTS and 34.6%
(12.1-97.7%) for CELLEX, p¼ <0.0001. With UVAR-XTS,
there were 19 (8%) procedures complicated by line oc-
clusions requiring TPA, and with CELLEX there were
4 (3%), p¼0.03. Patient-related complications included
need for pre-procedure blood transfusion and hemody-
namic changes. 32 (14%) of UVAR-XTS and 13 (8%) of
CELLEX procedures (p¼0.106) required patients to
receive blood product transfusions. 18 (8%) of UVAR-XTS
and 0 of CELLEX procedures were complicated by hy-
potension requiring ﬂuid boluses (p¼<0.0001). In 4 (2%)
UVAR-XTS and in 1 (<1%) CELLEX procedure (p¼0.653)
patients developed hypertension requiring anti-hyper-
tensive therapy.
Conclusions: This is the ﬁrst study in children comparing
efﬁciency, safety proﬁle, and percentage of cells processed
for Therakos UVAR-XTS versus CELLEX. Compared to
UVAR-XTS, CELLEX use results in shortened treatment
times, increased percentage of mononuclear cells treated per
procedure, reduced incidence of line occlusions requiring
TPA treatment, and decreased incidence of patient-related
complications, especially incidence of hypotension requiring
ﬂuid boluses.
